Evidence map›Paper›PMID 26513247›Full record

ArticlePloS one2015

In Vitro Mutational Analysis of the β2 Adrenergic Receptor, an In Vivo Surrogate Odorant Receptor.

Sophie Jamet, Jaclyn Bubnell, Patrick Pfister, Delia Tomoiaga, Matthew E Rogers, Paul Feinstein

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  4. Article
  5. Structural instability and divergence from conserved residues underlie intracellular retention of mammalian odorant receptors.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sophie JametDepartment of Biological Sciences, Hunter College, CUNY, New York, New York, United States of America.
Jaclyn BubnellDepartment of Biological Sciences, Hunter College, CUNY, New York, New York, United States of America.
Patrick PfisterCorporate Research and Development, Firmenich Inc., Plainsboro, New Jersey, United States of America.
Delia TomoiagaDepartment of Biological Sciences, Hunter College, CUNY, New York, New York, United States of America.
Matthew E RogersCorporate Research and Development, Firmenich Inc., Plainsboro, New Jersey, United States of America.
Paul FeinsteinDepartment of Biological Sciences, Hunter College, CUNY, New York, New York, United States of America; The Graduate Center Biology Program, CUNY, New York, New York, United States of America; The Graduate Center Behavioral and Cognitive Neuroscience Program, CUNY, New York, New York, United States of America.
Hunter College · USFirmenich (United States) · USThe Graduate Center, CUNY · US

Funding

Basic and Translational Research Center for Reducing Health DisparitiesG12MD007599 · NIMHD · HUNTER COLLEGE · PI ANGULO, JESUS A · 2012 to 2017
$14.6M
Regulation of Odorant Receptor Gene ExpressionSC1GM088114 · NIGMS · HUNTER COLLEGE · PI FEINSTEIN, PAUL · 2010 to 2014
$1.6M
NIGMS NIH HHS SC1 GM088114NIMHD NIH HHS G12 MD007599NIMHD NIH HHS MD007599
6 · The paper itself

Abstract

Many G-protein coupled receptors (GPCRs), such as odorant receptors (ORs), cannot be characterized in heterologous cells because of their difficulty in trafficking to the plasma membrane. In contrast, a surrogate OR, the GPCR mouse β2-adrenergic-receptor (mβ2AR), robustly traffics to the plasma membrane. We set out to characterize mβ2AR mutants in vitro for their eventual use in olfactory axon guidance studies. We performed an extensive mutational analysis of mβ2AR using a Green Fluorescent Protein-tagged mβ2AR (mβ2AR::GFP) to easily assess the extent of its plasma membrane localization. In order to characterize mutants for their ability to successfully transduce ligand-initiated signal cascades, we determined the half maximal effective concentrations (EC50) and maximal response to isoprenaline, a known mβ2AR agonist. Our analysis reveals that removal of amino terminal (Nt) N-glycosylation sites and the carboxy terminal (Ct) palmitoylation site of mβ2AR do not affect its plasma membrane localization. By contrast, when both the Nt and Ct of mβ2AR are replaced with those of M71 OR, plasma membrane trafficking is impaired. We further analyze three mβ2AR mutants (RDY, E268A, and C327R) used in olfactory axon guidance studies and are able to decorrelate their plasma membrane trafficking with their capacity to respond to isoprenaline. A deletion of the Ct prevents proper trafficking and abolishes activity, but plasma membrane trafficking can be selectively rescued by a Tyrosine to Alanine mutation in the highly conserved GPCR motif NPxxY. This new loss-of-function mutant argues for a model in which residues located at the end of transmembrane domain 7 can act as a retention signal when unmasked. Additionally, to our surprise, amongst our set of mutations only Ct mutations appear to lower mβ2AR EC50s revealing their critical role in G-protein coupling. We propose that an interaction between the Nt and Ct is necessary for proper folding and/or transport of GPCRs.

Indexed as

MutationAdrenergic beta-AgonistsAnimalsCell LineCell MembraneDNA Mutational AnalysisGene ExpressionGenes, ReporterGlycosylationHumansIsoproterenolMicePhenotypeProtein BindingProtein Interaction Domains and MotifsProtein TransportAdrenergic beta-AgonistsIsoproterenolReceptors, Adrenergic, beta-2Receptors, Odorant

Identifiers

PMID26513247
PMCPMC4626089
OpenAlexW2246811039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.